Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder characterized by tumor predisposition and a wide spectrum of neurologic manifestations. Among its most serious complications are plexiform neurofibromas (PNs), which can cause significant morbidity due to pain, disfigurement, neurologic impairment, and risk of malignant transformation. Despite advances in understanding NF1 biology, care remains complex and often fragmented across specialties, leading to delayed recognition and limited access to evolving therapies. Recent clinical evidence has established MEK inhibitors as targeted therapeutic options for NF1-associated PNs. Incorporating these therapies into practice requires careful patient selection, safety monitoring, and interprofessional coordination to ensure optimal outcomes.
This CEC Oncology recorded symposium will address these critical gaps by equipping neuro-oncologists, neurosurgeons, radiation oncologists, medical oncologists, advanced practitioners, and nurses with strategies for early recognition of NF1-associated tumors, effective integration of MEK inhibitors, and development of evidence-based, interprofessional care plans that support individualized, longitudinal management.
Learn More Here